Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

NEW YORK – Chinese genomic testing firm Genetron Health said Monday that it has partnered with Impact Therapeutics to support the firm's anti-cancer drug development efforts.

The two companies plan to work together to discover new targets and develop companion diagnostics for a class of drugs called synthetic lethal inhibitors, which most notably include PARP inhibitors.

Impact CEO Jun Bao said in a statement that the firm has already assembled a large pipeline of DNA damage response drug candidates. The company entered into a CDx partnership with Guangzhou, China-based sequencing firm Burning Rock Biotech for one of these, the PARP inhibitor senaparib.

Working with Genetron, Impact now aims to expand its pipeline further.

"We look forward to leveraging Genetron Health’s experience and resources in the field of precision oncology and working together with them to accelerate the research and development of new drugs, contributing to the global anti-cancer cause," Bao added.

Financial terms of the deal were not disclosed.